🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔔 Save the date! On line registration for the #CNICConference ‘Understanding immunity in cardiovascular disease’ is open until October 10. 📅 The Conference will take place on November 13-15, 2024 at CNIC Auditorium, Madrid. Registration is free of charge 📌

We are thrilled to announce the conference "Understanding Immunity in Cardiovascular Disease"! The registration period is open until October 10. Don't miss the chance to attend this meeting with terrific speakers in #Cardioimmunology. See you there! CNIC @CIBER_CV

La revolución de los microRNA ¿Por qué es tan importante el último Nobel de Medicina? abc.es/salud/revoluci… a través de ABC.es

SIR-CVT registry update at #CARDIOTOX24 presented by Pilar Martin from CNIC Thank you to all centers for an excellent work Soc Esp Cardiología SEOM CardioOncologia SEC Eduardo Zatarain

#cnicconference CNIC Enrique Ortega-Sollero Enrique Ortega-Sollero Pilar Martín Fernández gave a superb talk showing how CD69 deficiency increases susceptibility to anti-PD-1-induced myocarditis.

#CNICPhDay2024 CNIC PhDay the annual meeting organized by #PhD students and #PostdoctoralResearchers from CNIC, comes to an end! 🎉 This year’s theme, ‘Learning from the Past for a Better Future’, inspired fascinating discussions and innovative ideas.💡 Let’s keep

It was a great pleasure to contribute to this important work: 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology | JACC jacc.org/doi/10.1016/j.…

Our latest review in JCI is out - T cells in cardiac health and disease jci.org/articles/view/… CNIC @CIBER_CV

Immunometabolism masterclass from Pilar Martín Fernández at CNIC 🫀 #EMBOmetabolicDiseases EMBO Events EMBO Sonia Fdez-Veledo Ruben Nogueiras Guadalupe Sabio Roger J Davis

I am excited to share our latest review “T lymphocytes linking autoimmunity and cardiovascular disease in aging”published in The Journal of Cardiovascular Aging. 📖 Read the full article here: oaepublish.com/articles/jca.2…

Anti-mmu-mir-721 as a therapeutic target for immune checkpoint inhibitor-associated myocarditis #ESCardioOnco2025 Enrique Ortega-Sollero

Proud of the presentation of Enrique Ortega-Sollero in the Young Investigator Award session at the Exec Service Corps (E.S.C.) CardioOncology meeting #ESC_CardioOncology first meeting at Florence Italy!! Congratulations 🎉

Terrific work by Enrique Ortega-Sollero on a smart investigational therapy against ICI-related myocarditis #irAES Excited to see it published ‼️ Is it the time for "sponges"? #ESCardioOnco2025 CNIC Pilar Martín Fernández CIBER ISCIII

And award goes to..... Enrique Ortega-Sollero ‼️‼️‼️‼️ 👏🏽👏🏽👏🏽💪🏽💪🏽

An the winner is Enrique Ortega-Sollero !!!!! Congratulations Enrique from CNIC of the Young Investigator Award of the first #ESCardioOnco2025!!! European Society of Cardiology News . Well deserved!!!

Honored and grateful to receive the YIA! Huge thanks to the judges for this incredible distinction. CNIC #ESCardioOnco2025

📢 Great news! 🎉 The young CNIC researcher, Enrique Ortega-Sollero, has received the prestigious Young Investigator Award - Basic & Translational Research from the European Society of Cardiology during the #ESCardioOnco2025 🏆 His work “Anti-mmu-miR-721 as a therapeutic target for immune checkpoint

📢 ¡Gran noticia! 🎉 El joven investigador del CNIC, Enrique Ortega-Sollero, ha recibido el prestigioso Young Investigator Award – Basic & Translational Research de la European Society of Cardiology durante el #ESCardioOnco2025🏆 Su trabajo “Anti-mmu-miR-721 as a therapeutic target for immune

📣 Breakthrough in #ESCardioOnco2025! Research from Pilar Martín Fernández, CNIC and #CIBERCV, reveals immune changes predicting heart risks from #cancer drugs. 👩🏻‍⚕️ Dr. Martin explains: "Immune checkpoint inhibitors revolutionize cancer care but can harm the heart. We tracked